Pancreatic Cancer Drugs: A Global Market Report
Pancreatic cancer is typically very aggressive in nature, responds rather inadequately to treatment, and is generally diagnosed when it has already reached the locally advanced or metastatic stage. The rates of mortality tend to be high, and there exists no therapy that is shown to significantly improve survival. Only a few systemic treatments are available, and just about 20% of the patients diagnosed with a resectable disease are eligible to receive the systemic therapy.
View full press release